Biocytogen

Biocytogen is a biotechnology company founded in 2008 in Massachusetts, USA, and established in Beijing, China, in 2009. It operates globally, with a focus on gene-targeted animal model production, preclinical in vivo efficacy studies, and pharmacological services. The company is recognized as a leader in these fields, utilizing innovative gene editing technologies and proprietary platforms. Biocytogen offers a range of services, including custom gene targeting using its CRISPR-based Extreme Genome Editing technology, which enhances the efficiency of gene modifications. The company also provides high-throughput antibody discovery services and preclinical efficacy evaluations using humanized mouse models. Its platforms, such as RenMab® and RenLite®, support the discovery of fully human antibodies, while the RenNano Platform focuses on nanobody development. Biocytogen collaborates with numerous biotech and pharmaceutical companies, advancing antibody drug discovery and development. The company is publicly listed on the Hong Kong Stock Exchange and has expanded its operations with new facilities in Boston and Shanghai.